| Literature DB >> 21275961 |
Winfred Wang1, Carlo Brugnara, Cathie Snyder, Lynn Wynn, Zora Rogers, Karen Kalinyak, Clark Brown, Asif Qureshi, Carolyn Bigelow, Lynne Neumayr, Kim Smith-Whitley, David H K Chui, Mardee Delahunty, Rob Woolson, Martin Steinberg, Marilyn Telen, Karen Kesler.
Abstract
In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21275961 DOI： 10.1111/j.1365-2141.2010.08523.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998